Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.

IF 4.7 2区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
European Radiology Pub Date : 2025-03-01 Epub Date: 2024-10-19 DOI:10.1007/s00330-024-11140-5
Aynur Azizova, Yeva Prysiazhniuk, Ivar J H G Wamelink, Marcus Cakmak, Elif Kaya, Pieter Wesseling, Philip C de Witt Hamer, Niels Verburg, Jan Petr, Frederik Barkhof, Vera C Keil
{"title":"Preoperative prediction of diffuse glioma type and grade in adults: a gadolinium-free MRI-based decision tree.","authors":"Aynur Azizova, Yeva Prysiazhniuk, Ivar J H G Wamelink, Marcus Cakmak, Elif Kaya, Pieter Wesseling, Philip C de Witt Hamer, Niels Verburg, Jan Petr, Frederik Barkhof, Vera C Keil","doi":"10.1007/s00330-024-11140-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To develop a gadolinium-free MRI-based diagnosis prediction decision tree (DPDT) for adult-type diffuse gliomas and to assess the added value of gadolinium-based contrast agent (GBCA) enhanced images.</p><p><strong>Materials and methods: </strong>This study included preoperative grade 2-4 adult-type diffuse gliomas (World Health Organization 2021) scanned between 2010 and 2021. The DPDT, incorporating eleven GBCA-free MRI features, was developed using 18% of the dataset based on consensus readings. Diagnosis predictions involved grade (grade 2 vs. grade 3/4) and molecular status (isocitrate dehydrogenase (IDH) and 1p/19q). GBCA-free diagnosis was predicted using DPDT, while GBCA-enhanced diagnosis included post-contrast images. The accuracy of these predictions was assessed by three raters with varying experience levels in neuroradiology using the test dataset. Agreement analyses were applied to evaluate the prediction performance/reproducibility.</p><p><strong>Results: </strong>The test dataset included 303 patients (age (SD): 56.7 (14.2) years, female/male: 114/189, low-grade/high-grade: 54/249, IDH-mutant/wildtype: 82/221, 1p/19q-codeleted/intact: 34/269). Per-rater GBCA-free predictions achieved ≥ 0.85 (95%-CI: 0.80-0.88) accuracy for grade and ≥ 0.75 (95%-CI: 0.70-0.80) for molecular status, while GBCA-enhanced predictions reached ≥ 0.87 (95%-CI: 0.82-0.90) and ≥ 0.77 (95%-CI: 0.71-0.81), respectively. No accuracy difference was observed between GBCA-free and GBCA-enhanced predictions. Group inter-rater agreement was moderate for GBCA-free (0.56 (95%-CI: 0.46-0.66)) and substantial for GBCA-enhanced grade prediction (0.68 (95%-CI: 0.58-0.78), p = 0.008), while substantial for both GBCA-free (0.75 (95%-CI: 0.69-0.80) and GBCA-enhanced (0.77 (95%-CI: 0.71-0.82), p = 0.51) molecular status predictions.</p><p><strong>Conclusion: </strong>The proposed GBCA-free diagnosis prediction decision tree performed well, with GBCA-enhanced images adding little to the preoperative diagnostic accuracy of adult-type diffuse gliomas.</p><p><strong>Key points: </strong>Question Given health and environmental concerns, is there a gadolinium-free imaging protocol to preoperatively evaluate gliomas comparable to the gadolinium-enhanced standard practice? Findings The proposed gadolinium-free diagnosis prediction decision tree for adult-type diffuse gliomas performed well, and gadolinium-enhanced MRI demonstrated only limited improvement in diagnostic accuracy. Clinical relevance Even inexperienced raters effectively classified adult-type diffuse gliomas using the gadolinium-free diagnosis prediction decision tree, which, until further validation, can be used alongside gadolinium-enhanced images to respect standard practice, despite this study showing that gadolinium-enhanced images hardly improved diagnostic accuracy.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"1242-1254"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836213/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00330-024-11140-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To develop a gadolinium-free MRI-based diagnosis prediction decision tree (DPDT) for adult-type diffuse gliomas and to assess the added value of gadolinium-based contrast agent (GBCA) enhanced images.

Materials and methods: This study included preoperative grade 2-4 adult-type diffuse gliomas (World Health Organization 2021) scanned between 2010 and 2021. The DPDT, incorporating eleven GBCA-free MRI features, was developed using 18% of the dataset based on consensus readings. Diagnosis predictions involved grade (grade 2 vs. grade 3/4) and molecular status (isocitrate dehydrogenase (IDH) and 1p/19q). GBCA-free diagnosis was predicted using DPDT, while GBCA-enhanced diagnosis included post-contrast images. The accuracy of these predictions was assessed by three raters with varying experience levels in neuroradiology using the test dataset. Agreement analyses were applied to evaluate the prediction performance/reproducibility.

Results: The test dataset included 303 patients (age (SD): 56.7 (14.2) years, female/male: 114/189, low-grade/high-grade: 54/249, IDH-mutant/wildtype: 82/221, 1p/19q-codeleted/intact: 34/269). Per-rater GBCA-free predictions achieved ≥ 0.85 (95%-CI: 0.80-0.88) accuracy for grade and ≥ 0.75 (95%-CI: 0.70-0.80) for molecular status, while GBCA-enhanced predictions reached ≥ 0.87 (95%-CI: 0.82-0.90) and ≥ 0.77 (95%-CI: 0.71-0.81), respectively. No accuracy difference was observed between GBCA-free and GBCA-enhanced predictions. Group inter-rater agreement was moderate for GBCA-free (0.56 (95%-CI: 0.46-0.66)) and substantial for GBCA-enhanced grade prediction (0.68 (95%-CI: 0.58-0.78), p = 0.008), while substantial for both GBCA-free (0.75 (95%-CI: 0.69-0.80) and GBCA-enhanced (0.77 (95%-CI: 0.71-0.82), p = 0.51) molecular status predictions.

Conclusion: The proposed GBCA-free diagnosis prediction decision tree performed well, with GBCA-enhanced images adding little to the preoperative diagnostic accuracy of adult-type diffuse gliomas.

Key points: Question Given health and environmental concerns, is there a gadolinium-free imaging protocol to preoperatively evaluate gliomas comparable to the gadolinium-enhanced standard practice? Findings The proposed gadolinium-free diagnosis prediction decision tree for adult-type diffuse gliomas performed well, and gadolinium-enhanced MRI demonstrated only limited improvement in diagnostic accuracy. Clinical relevance Even inexperienced raters effectively classified adult-type diffuse gliomas using the gadolinium-free diagnosis prediction decision tree, which, until further validation, can be used alongside gadolinium-enhanced images to respect standard practice, despite this study showing that gadolinium-enhanced images hardly improved diagnostic accuracy.

成人弥漫性胶质瘤类型和分级的术前预测:基于无钆磁共振成像的决策树。
目的开发基于无钆磁共振成像的成人型弥漫性胶质瘤诊断预测决策树(DPDT),并评估钆基造影剂(GBCA)增强图像的附加值:本研究包括2010年至2021年期间扫描的术前2-4级成人型弥漫性胶质瘤(世界卫生组织2021年版)。在共识读数的基础上,利用数据集的 18% 开发了 DPDT,其中包含 11 个不含 GBCA 的磁共振成像特征。诊断预测涉及等级(2 级与 3/4 级)和分子状态(异柠檬酸脱氢酶 (IDH) 和 1p/19q)。使用 DPDT 预测无 GBCA 诊断,而 GBCA 增强诊断包括对比后图像。三名具有不同神经放射学经验水平的评分员使用测试数据集对这些预测的准确性进行了评估。采用一致性分析来评估预测性能/可重复性:测试数据集包括 303 名患者(年龄(SD):56.7(14.2)岁,女性/男性:114/189,低级别/高级别:54/249,IDH-畸形/野生型:82/221,1p/19kb/mRNA:1/19kb/mRNA:1/19kb/mRNA:1/19kb:82/221, 1p/19q-codeleted/intact:34/269).每个评分者无 GBCA 预测的分级准确率≥ 0.85(95%-CI:0.80-0.88),分子状态准确率≥ 0.75(95%-CI:0.70-0.80),而 GBCA 增强预测的准确率分别≥ 0.87(95%-CI:0.82-0.90)和≥ 0.77(95%-CI:0.71-0.81)。无 GBCA 预测和 GBCA 增强预测之间未观察到准确性差异。对于无 GBCA(0.56 (95%-CI: 0.46-0.66))和 GBCA 增强分级预测(0.68 (95%-CI: 0.58-0.78),p = 0.008),组间评分者一致性为中度,而对于无 GBCA(0.75 (95%-CI: 0.69-0.80))和 GBCA 增强(0.77 (95%-CI: 0.71-0.82),p = 0.51)分子状态预测,组间评分者一致性为高度:结论:建议的无GBCA诊断预测决策树表现良好,GBCA增强图像对成人型弥漫性胶质瘤的术前诊断准确性几乎没有影响:问题 鉴于健康和环境问题,是否有一种无钆成像方案可用于术前评估胶质瘤,与钆增强标准做法相媲美?研究结果 针对成人型弥漫性胶质瘤提出的无钆诊断预测决策树表现良好,而钆增强 MRI 对诊断准确性的提高有限。临床相关性 尽管本研究显示钆增强图像几乎没有提高诊断准确性,但即使是缺乏经验的评分员也能使用无钆诊断预测决策树有效地对成人型弥漫性胶质瘤进行分类。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Radiology
European Radiology 医学-核医学
CiteScore
11.60
自引率
8.50%
发文量
874
审稿时长
2-4 weeks
期刊介绍: European Radiology (ER) continuously updates scientific knowledge in radiology by publication of strong original articles and state-of-the-art reviews written by leading radiologists. A well balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes ER an indispensable source for current information in this field. This is the Journal of the European Society of Radiology, and the official journal of a number of societies. From 2004-2008 supplements to European Radiology were published under its companion, European Radiology Supplements, ISSN 1613-3749.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信